Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
Go back to Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)| ESPERION THERAP (NASDAQ: ESPR) | Delayed: 3.16 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.16 | 52 Week High | $30.41 | |||
| Open | $3.16 | 52 Week Low | $9.40 | |||
| Day High | $3.17 | P/E | N/A | |||
| Day Low | $3.15 | EPS | $-21.87 | |||
| Volume | 4,737,393 | |||||
